|
WO2019195609A2
(en)
|
2018-04-04 |
2019-10-10 |
Arvinas Operations, Inc. |
Modulators of proteolysis and associated methods of use
|
|
WO2019217307A1
(en)
|
2018-05-07 |
2019-11-14 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
JP2022500385A
(ja)
|
2018-09-10 |
2022-01-04 |
ミラティ セラピューティクス， インコーポレイテッド |
組み合わせ療法
|
|
EP3849537B1
(en)
|
2018-09-10 |
2024-10-23 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
EA202190749A1
(ru)
|
2018-09-10 |
2021-07-09 |
Мирати Терапьютикс, Инк. |
Способы комбинированной терапии
|
|
EP3849535A4
(en)
|
2018-09-10 |
2022-06-29 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
WO2020085504A1
(ja)
|
2018-10-26 |
2020-04-30 |
大鵬薬品工業株式会社 |
光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
|
|
MX2021002804A
(es)
|
2018-12-05 |
2021-07-15 |
Mirati Therapeutics Inc |
Terapias de combinacion.
|
|
EP3908283A4
(en)
|
2019-01-10 |
2022-10-12 |
Mirati Therapeutics, Inc. |
KRAS G12C INHIBITORS
|
|
MX2022002465A
(es)
|
2019-08-29 |
2022-05-19 |
Mirati Therapeutics Inc |
Inhibidores de kras g12d.
|
|
WO2021061749A1
(en)
|
2019-09-24 |
2021-04-01 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
UA129778C2
(uk)
|
2019-10-28 |
2025-07-30 |
Мерк Шарп Енд Доум Елелсі |
Низькомолекулярні інгібітори g12c-мутантного kras
|
|
EP4067343A4
(en)
|
2019-11-29 |
2024-01-03 |
Taiho Pharmaceutical Co., Ltd. |
NEW PHENOLIC COMPOUND OR SALT THEREOF
|
|
WO2021109737A1
(zh)
*
|
2019-12-02 |
2021-06-10 |
上海璎黎药业有限公司 |
一种含氧杂环化合物、其制备方法及应用
|
|
PH12022551513A1
(en)
|
2019-12-20 |
2023-04-24 |
Mirati Therapeutics Inc |
Sos1 inhibitors
|
|
IL299131A
(en)
|
2020-06-18 |
2023-02-01 |
Revolution Medicines Inc |
Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
|
|
WO2022002102A1
(en)
*
|
2020-06-30 |
2022-01-06 |
InventisBio Co., Ltd. |
Quinazoline compounds, preparation methods and uses thereof
|
|
US20250195521A1
(en)
|
2020-09-03 |
2025-06-19 |
Revolution Medicines, Inc. |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
EP4210833A4
(en)
|
2020-09-11 |
2024-09-11 |
Mirati Therapeutics, Inc. |
CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
|
|
US20230357277A1
(en)
|
2020-09-22 |
2023-11-09 |
Mirati Therapeutics, Inc. |
Kras g12d inhibitors
|
|
WO2022068921A1
(zh)
*
|
2020-09-30 |
2022-04-07 |
上海医药集团股份有限公司 |
一种喹唑啉类化合物及其应用
|
|
WO2022098625A1
(en)
|
2020-11-03 |
2022-05-12 |
Mirati Therapeutics, Inc. |
Kras g12d inhibitors
|
|
WO2022105859A1
(en)
*
|
2020-11-20 |
2022-05-27 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras g12d inhibitors
|
|
WO2022105855A1
(en)
*
|
2020-11-20 |
2022-05-27 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras g12d inhibitors
|
|
CN116490508A
(zh)
*
|
2020-11-20 |
2023-07-25 |
北京加科思新药研发有限公司 |
Kras g12d抑制剂
|
|
JP2023553492A
(ja)
|
2020-12-15 |
2023-12-21 |
ミラティ セラピューティクス， インコーポレイテッド |
アザキナゾリン汎ＫＲａｓ阻害剤
|
|
EP4262803A4
(en)
|
2020-12-16 |
2025-03-12 |
Mirati Therapeutics, Inc. |
Tetrahydropyridopyrimidine pan-kras inhibitors
|
|
US20240092803A1
(en)
*
|
2021-01-08 |
2024-03-21 |
Beigene Switzerland Gmbh |
Bridged compounds as kras g12d inhibitor and degrader and the use thereof
|
|
WO2022148422A1
(en)
*
|
2021-01-08 |
2022-07-14 |
Beigene, Ltd. |
Bridged compounds as kras g12d inhibitor and degrader and the use thereof
|
|
MX2023009037A
(es)
*
|
2021-02-01 |
2023-08-10 |
Medshine Discovery Inc |
Compuesto de pirimidopirano.
|
|
WO2022170999A1
(zh)
*
|
2021-02-09 |
2022-08-18 |
南京明德新药研发有限公司 |
吡啶[4，3-d]嘧啶类化合物
|
|
KR20230136636A
(ko)
*
|
2021-02-09 |
2023-09-26 |
메드샤인 디스커버리 아이엔씨. |
피리미딘 방향족 환 화합물
|
|
WO2022171143A1
(zh)
*
|
2021-02-09 |
2022-08-18 |
南京明德新药研发有限公司 |
5,6,7,8-四氢吡啶[3,4-d]嘧啶化合物
|
|
EP4293025B1
(en)
*
|
2021-02-15 |
2025-10-29 |
Astellas Pharma Inc. |
4-aminoquinazoline compound
|
|
WO2022173032A1
(ja)
|
2021-02-15 |
2022-08-18 |
アステラス製薬株式会社 |
Ｇ１２ｄ変異ｋｒａｓタンパクの分解を誘導するためのキナゾリン化合物
|
|
MX2023010430A
(es)
*
|
2021-03-12 |
2023-09-12 |
Bristol Myers Squibb Co |
Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d).
|
|
TWI810803B
(zh)
*
|
2021-03-15 |
2023-08-01 |
大陸商藥雅科技（上海）有限公司 |
突變蛋白抑制劑的製備及其應用
|
|
CN116964058A
(zh)
*
|
2021-03-15 |
2023-10-27 |
贝达药业股份有限公司 |
Kras g12d抑制剂及其在医药上的应用
|
|
WO2022194192A1
(zh)
*
|
2021-03-18 |
2022-09-22 |
四川科伦博泰生物医药股份有限公司 |
一类杂芳环化合物、其制备方法及用途
|
|
CN116157400B
(zh)
*
|
2021-03-30 |
2024-10-22 |
浙江海正药业股份有限公司 |
杂环类衍生物及其制备方法和用途
|
|
WO2022217042A1
(en)
*
|
2021-04-09 |
2022-10-13 |
Ikena Oncology, Inc. |
Naphthyl-substituted quinoline-4(1h)-ones and related compounds and their use in treating medical conditions
|
|
CN117203208A
(zh)
*
|
2021-04-23 |
2023-12-08 |
清华大学 |
靶向活化与失活态kras g12d的抑制剂
|
|
US20250059205A1
(en)
*
|
2021-04-29 |
2025-02-20 |
Amgen Inc. |
Heterocyclic Compounds and Methods of Use
|
|
CN117222650A
(zh)
*
|
2021-04-30 |
2023-12-12 |
劲方医药科技(上海)有限公司 |
吡啶或嘧啶并环类化合物，其制法与医药上的用途
|
|
JP2024516450A
(ja)
|
2021-05-05 |
2024-04-15 |
レボリューション メディシンズ インコーポレイテッド |
共有結合性ｒａｓ阻害剤及びその使用
|
|
CN115385937A
(zh)
*
|
2021-05-25 |
2022-11-25 |
江苏恒瑞医药股份有限公司 |
嘧啶并环烷基类化合物、其制备方法及其在医药上的应用
|
|
EP4347041A1
(en)
*
|
2021-05-28 |
2024-04-10 |
Taiho Pharmaceutical Co., Ltd. |
Small molecule inhibitors of kras mutated proteins
|
|
WO2022261154A1
(en)
*
|
2021-06-09 |
2022-12-15 |
Eli Lilly And Company |
Substituted fused azines as kras g12d inhibitors
|
|
BR112023025869A2
(pt)
*
|
2021-06-10 |
2024-02-27 |
Redx Pharma Plc |
Derivados de quinazolina úteis como inibidores de ras
|
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
TW202317580A
(zh)
*
|
2021-06-18 |
2023-05-01 |
大陸商南京燧坤智能科技有限公司 |
用作ｋｒａｓ ｇ１２ｄ抑制劑的氘代化合物
|
|
EP4361157A4
(en)
*
|
2021-06-21 |
2024-10-16 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
FUSED TETRACYCLIC COMPOUND, ITS PREPARATION METHOD AND ITS USE IN MEDICINE
|
|
EP4363412A4
(en)
*
|
2021-06-30 |
2025-05-14 |
Dana-Farber Cancer Institute, Inc. |
Small-molecule inhibitors of the KRAS G12D mutant
|
|
CN117460737A
(zh)
*
|
2021-07-05 |
2024-01-26 |
四川科伦博泰生物医药股份有限公司 |
杂芳环化合物、其制备方法及用途
|
|
CN117751116A
(zh)
*
|
2021-07-07 |
2024-03-22 |
微境生物医药科技(上海)有限公司 |
作为KRas G12D抑制剂的稠环化合物
|
|
TW202317589A
(zh)
*
|
2021-07-14 |
2023-05-01 |
美商尼坎醫療公司 |
作為ｋｒａｓ抑制劑的伸烷基衍生物
|
|
WO2023284537A1
(en)
*
|
2021-07-16 |
2023-01-19 |
Shanghai Zion Pharma Co. Limited |
Kras g12d inhibitors and uses thereof
|
|
WO2023284881A1
(en)
*
|
2021-07-16 |
2023-01-19 |
Silexon Ai Technology Co., Ltd. |
Heterocyclic compounds useful as kras g12d inhibitors
|
|
WO2023283933A1
(en)
*
|
2021-07-16 |
2023-01-19 |
Silexon Biotech Co., Ltd. |
Compounds useful as kras g12d inhibitors
|
|
KR20240041917A
(ko)
|
2021-07-27 |
2024-04-01 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방을 위한 의약품
|
|
KR20230022816A
(ko)
*
|
2021-08-06 |
2023-02-16 |
인터올리고 주식회사 |
올리고뉴클레오티드를 유효성분으로 포함하는 삼중음성 유방암을 예방 또는 치료하기 위한 약학적 조성물
|
|
TW202321261A
(zh)
*
|
2021-08-10 |
2023-06-01 |
美商伊瑞斯卡公司 |
選擇性ｋｒａｓ抑制劑
|
|
KR20240046745A
(ko)
*
|
2021-08-12 |
2024-04-09 |
머크 샤프 앤드 돔 엘엘씨 |
벨주티판의 투여를 위한 투여량 레지멘
|
|
CN116669740A
(zh)
*
|
2021-08-16 |
2023-08-29 |
华润医药研究院（深圳）有限公司 |
嘧啶并吡啶类化合物及其制备方法和医药用途
|
|
CN117858878A
(zh)
*
|
2021-08-18 |
2024-04-09 |
北京加科思新药研发有限公司 |
N-环丙基吡啶并[4,3-d]嘧啶-4-胺衍生物及其用途
|
|
UY39906A
(es)
*
|
2021-08-18 |
2023-03-31 |
Jacobio Pharmaceuticals Co Ltd |
Derivados de 1,4-oxazepano y usos de los mismos
|
|
WO2023040989A1
(en)
*
|
2021-09-16 |
2023-03-23 |
Suzhou Zanrong Pharma Limited |
Kras g12c inhibitors and uses thereof
|
|
WO2023051586A1
(zh)
*
|
2021-09-29 |
2023-04-06 |
先声再明医药有限公司 |
Kras g12d抑制剂化合物及其制备方法和应用
|
|
CN118401254A
(zh)
*
|
2021-10-05 |
2024-07-26 |
米拉蒂治疗股份有限公司 |
Kras g12d抑制剂与shp-2抑制剂的组合疗法
|
|
MX2024004216A
(es)
|
2021-10-05 |
2024-06-20 |
Mirati Therapeutics Inc |
Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb.
|
|
AU2022361219A1
(en)
*
|
2021-10-05 |
2024-04-11 |
Mirati Therapeutics, Inc. |
Combinations of kras g12d inhibitors with irinotecan and related methods of treatment
|
|
IL311834A
(en)
|
2021-10-05 |
2024-05-01 |
Mirati Therapeutics Inc |
Combinations of KRAS G12D inhibitors with PI3KA inhibitors and therapeutic methods
|
|
EP4419686A4
(en)
*
|
2021-10-21 |
2025-10-15 |
Nanothera Biosciences Inc |
COMPOSITIONS AND METHODS OF EXTINGUISHING KRAS
|
|
CN114057776A
(zh)
*
|
2021-10-31 |
2022-02-18 |
南京碳硅人工智能生物医药技术研究院有限公司 |
一种具有抗癌活性的嘧啶并哌啶衍生物的新合成方法
|
|
CN116253748A
(zh)
*
|
2021-12-09 |
2023-06-13 |
苏州浦合医药科技有限公司 |
取代的双环杂芳基化合物作为kras g12d抑制剂
|
|
WO2023119677A1
(en)
*
|
2021-12-24 |
2023-06-29 |
Astellas Pharma Inc. |
Pharmaceutical composition comprising a quinazoline compound
|
|
WO2023125989A1
(zh)
*
|
2021-12-31 |
2023-07-06 |
上海医药集团股份有限公司 |
一种喹唑啉类化合物及其应用
|
|
CA3249537A1
(en)
*
|
2022-01-21 |
2025-06-17 |
D3 Bio (Wuxi) Co., Ltd. |
HETEROARYL-PYRANE DERIVATIVE SUBSTITUTED BY A BRIDGED CYCLE AND ITS USE
|
|
EP4371991A4
(en)
*
|
2022-01-21 |
2025-02-26 |
Usynova Pharmaceuticals Ltd. |
Benzopyrimidine compounds and use thereof
|
|
WO2023138524A1
(zh)
*
|
2022-01-24 |
2023-07-27 |
贝达药业股份有限公司 |
Kras g12d降解剂及其在医药上的应用
|
|
CA3243798A1
(en)
|
2022-02-09 |
2023-08-17 |
Quanta Therapeutics, Inc. |
Kras Modulators and Their Uses
|
|
WO2023152255A1
(en)
*
|
2022-02-10 |
2023-08-17 |
Bayer Aktiengesellschaft |
Fused pyrimidines as kras inhibitors
|
|
TW202346270A
(zh)
|
2022-03-11 |
2023-12-01 |
日商安斯泰來製藥股份有限公司 |
用於誘發g12d突變kras蛋白分解之雜環化合物
|
|
WO2023179629A1
(zh)
*
|
2022-03-22 |
2023-09-28 |
苏州泽璟生物制药股份有限公司 |
取代桥环类抑制剂及其制备方法和应用
|
|
CN116891488B
(zh)
|
2022-04-11 |
2025-12-12 |
成都海博为药业有限公司 |
稠环化合物、包含其的药物组合物及应用
|
|
CN114989195B
(zh)
*
|
2022-05-25 |
2024-10-29 |
广东晨康生物科技有限公司 |
一种噻吩并嘧啶类化合物或其药学上可接受的盐及其制备方法和应用
|
|
WO2023230190A1
(en)
|
2022-05-25 |
2023-11-30 |
Quanta Therapeutics, Inc. |
Pyrimidine based modulators and uses thereof
|
|
CN117164580A
(zh)
*
|
2022-05-27 |
2023-12-05 |
苏州泽璟生物制药股份有限公司 |
一种kras g12c抑制剂的制备方法及其中间体
|
|
AU2023289822A1
(en)
*
|
2022-06-24 |
2025-01-30 |
Medshine Discovery Inc. |
Heterocyclic substituted pyrimidopyran compound and use thereof
|
|
US20250145631A1
(en)
|
2022-07-21 |
2025-05-08 |
Astellas Pharma Inc. |
Heterocyclic compound acting on g12d mutant kras protein
|
|
AU2023314335A1
(en)
*
|
2022-07-29 |
2025-02-27 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmaceutical composition comprising kras g12d inhibitor
|
|
TW202412789A
(zh)
|
2022-08-05 |
2024-04-01 |
日商安斯泰來製藥股份有限公司 |
用於誘導突變kras蛋白分解之雜環化合物
|
|
AR130191A1
(es)
|
2022-08-12 |
2024-11-13 |
Astellas Pharma Inc |
Combinaciones antineoplásicas que comprenden tratamiento dirigido
|
|
AR130192A1
(es)
*
|
2022-08-12 |
2024-11-13 |
Astellas Pharma Inc |
Combinaciones antineoplásicas que comprenden quimioterapia
|
|
EP4573095A1
(en)
|
2022-08-17 |
2025-06-25 |
Treeline Biosciences, Inc. |
Pyridopyrimidine kras inhibitors
|
|
US20260083750A1
(en)
*
|
2022-08-26 |
2026-03-26 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras proteins
|
|
WO2024064335A1
(en)
*
|
2022-09-23 |
2024-03-28 |
Ikena Oncology, Inc. |
Naphthyl-substituted pyranopyrimidinones and related compounds and their use in treating medical conditions
|
|
CN117800976A
(zh)
*
|
2022-09-30 |
2024-04-02 |
上海凌达生物医药有限公司 |
一类含氮杂环类化合物、制备方法和用途
|
|
JP2025536369A
(ja)
|
2022-10-21 |
2025-11-05 |
リーディングタック ファーマシューティカル（シャオシン）カンパニー，リミテッド |
Ｋｒａｓ ｇ１２ｄ分解剤及びその製造方法並びに応用
|
|
EP4631942A1
(en)
|
2022-10-21 |
2025-10-15 |
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. |
Pan-kras degrading agent, and preparation method therefor and use thereof
|
|
CN116554208A
(zh)
*
|
2022-12-02 |
2023-08-08 |
苏州浦合医药科技有限公司 |
取代的双环杂芳基化合物作为kras g12d抑制剂
|
|
US12448399B2
(en)
|
2023-01-26 |
2025-10-21 |
Arvinas Operations, Inc. |
Cereblon-based KRAS degrading PROTACs and uses related thereto
|
|
KR20260041941A
(ko)
|
2023-03-15 |
2026-03-27 |
콴타 테라퓨틱스, 인크. |
Kras 조절 인자 및 이의 용도
|
|
JP2026511123A
(ja)
*
|
2023-03-23 |
2026-04-10 |
徳昇済医薬（無錫）有限公司 |
複素環置換ピリミドピラン化合物及びその使用
|
|
KR20260016466A
(ko)
*
|
2023-03-27 |
2026-02-03 |
셴젠 이오노바 라이프 사이언스 시오., 엘티디. |
Kras(g12d) 단백질의 분해 및 억제를 위한 화합물
|
|
AU2024241633A1
(en)
|
2023-03-30 |
2025-11-06 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
TW202508595A
(zh)
|
2023-05-04 |
2025-03-01 |
美商銳新醫藥公司 |
用於ｒａｓ相關疾病或病症之組合療法
|
|
PE20252789A1
(es)
|
2023-05-24 |
2025-12-22 |
Kumquat Biosciences Inc |
Compuestos heterociclicos y usos de estos
|
|
AR133027A1
(es)
|
2023-06-22 |
2025-08-20 |
Astellas Pharma Inc |
Composición farmacéutica que comprende un compuesto de quinazolina
|
|
AR133028A1
(es)
|
2023-06-22 |
2025-08-20 |
Astellas Pharma Inc |
Composición farmacéutica que comprende un degradador de todas las kras
|
|
WO2025019823A1
(en)
*
|
2023-07-20 |
2025-01-23 |
Merck Sharp & Dohme Llc |
Small molecule protein degraders of kras g12d mutant
|
|
WO2025026903A1
(en)
*
|
2023-07-31 |
2025-02-06 |
Bayer Aktiengesellschaft |
Imidazo pyrimidine compounds for the treatment of cancer
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
TW202528315A
(zh)
|
2023-09-21 |
2025-07-16 |
美商樹線生物科學公司 |
螺環二氫哌喃并吡啶ＫＲａｓ抑制劑
|
|
US20250114346A1
(en)
|
2023-10-09 |
2025-04-10 |
Incyte Corporation |
Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
|
|
US20250114339A1
(en)
|
2023-10-09 |
2025-04-10 |
Incyte Corporation |
Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
AU2024361909A1
(en)
|
2023-10-20 |
2026-03-26 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras proteins
|
|
WO2025108479A1
(en)
*
|
2023-11-24 |
2025-05-30 |
Shenzhen Ionova Life Science Co., Ltd. |
Compounds for degradation or inhibition of kras mutant proteins and uses thereof
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025218811A1
(zh)
*
|
2024-04-19 |
2025-10-23 |
领泰生物医药(绍兴)有限公司 |
pan-KRAS靶向蛋白降解剂及其制备方法和应用
|
|
WO2025230961A1
(en)
*
|
2024-04-29 |
2025-11-06 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras proteins
|
|
WO2025240740A1
(en)
*
|
2024-05-15 |
2025-11-20 |
Merck Sharp & Dohme Llc |
Small molecule protein degraders of kras g12d mutant
|
|
TW202547461A
(zh)
|
2024-05-17 |
2025-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025245127A1
(en)
|
2024-05-21 |
2025-11-27 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|